Meridian Bioscience (VIVO) Cash Flow Statement

Click line-items for a historical chart and %

Net earnings
Depreciation of property, plant and equipment	3.94M
Amortization of intangible assets	2.69M
Amortization of deferred illumigene contract costs
Stock-based compensation	2.91M
Deferred income taxes	-233K
Loss on disposition of fixed assets	659K
Unrealized loss on auction-rate securities and rights, net
Change in current assets
Change in current liabilities
Other, net
Net cash provided by operating activities
Purchases of property, plant and equipment	-4M
Purchases of intangibles and other assets	0
Purchases of short-term investments
Proceeds from sales and calls of short-term investments
Net cash (used for) provided by investing activities
Dividends paid	-33.65M
Proceeds and tax benefits from exercises of stock options	2.49M
Net cash used for financing activities
Effect of Exchange Rate Changes on Cash and Equivalents
Net (Decrease) Increase in Cash and Equivalents	-2.75M
Cash and Equivalents at Beginning of Period	49.97M
Cash and Equivalents at End of Period	47.23M

Entities mentioned with VIVO

View All Entities